Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311 | Director | April 15, 2019 | April 16, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ORAMED PHARMACEUTICALS INC.
Report date April 15, 2019 · Filed April 16, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.13 · Expires 2029-04-15 | Direct | 20,000 |
Reported balance
After 2019-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-04-15 · Grant · Acquired 20,000 · Balance 20,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 15, 2019 Filed Apr 16, 2019 21:01 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001213900-19-006513 · ownership.xml · derivative · entry 1 Slager David Mark · CIK 0001477733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-04-15 Read SEC document |
| October 31, 2017 Filed Nov 1, 2017 20:39 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionWarrant (right to buy) · Derivative | 16,892 | $1.18 Strike: $3.77 | $19,925.80 |
DisclosureSEC source: 0001213900-17-011195 · f4103117slager_oramedpharm.xml · derivative · entry 2 Slager David Mark · CIK 0001477733 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Regals Fund LP Disclosed balance after: 0 Underlying: Common Stock · 16,892 shares Expires 2017-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013. F3 · price: The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model. Read SEC document |
| October 31, 2017 Filed Nov 1, 2017 20:39 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionCommon Stock | 16,892 | $3.77 | $63,608.52 |
DisclosureSEC source: 0001213900-17-011195 · f4103117slager_oramedpharm.xml · nonDerivative · entry 1 Slager David Mark · CIK 0001477733 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Regals Fund LP Disclosed balance after: 1,316,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Mr. Slager is Managing Member of the general partner of Regals Capital Management LP ("Regals Management"). Regals Management is the investment manager of Regals Fund LP (the "Fund"). The securities reported herein are held for the account of the Fund. Pursuant to Rule 16a-1(a)(4) under the Act, Mr. Slager disclaims beneficial ownership in the securities owned by the Fund except to the extent, if any, of his pecuniary interest therein. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 17:56 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionWarrant (right to buy) · Derivative | 112,613 | $1.18 Strike: $3.77 | $132,838.29 |
DisclosureSEC source: 0001213900-17-008982 · f4081717slager_oramendpharm.xml · derivative · entry 2 Slager David Mark · CIK 0001477733 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Regals Fund LP Disclosed balance after: 0 Underlying: Common Stock · 112,613 shares Expires 2017-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013. F3 · price: The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 17:56 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionCommon Stock | 112,613 | $3.77 | $424,055.51 |
DisclosureSEC source: 0001213900-17-008982 · f4081717slager_oramendpharm.xml · nonDerivative · entry 1 Slager David Mark · CIK 0001477733 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Regals Fund LP Disclosed balance after: 1,299,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Mr. Slager is Managing Member of the general partner of Regals Capital Management LP ("Regals Management"). Regals Management is the investment manager of Regals Fund LP (the "Fund"). The securities reported herein are held for the account of the Fund. Pursuant to Rule 16a-1(a)(4) under the Act, Mr. Slager disclaims beneficial ownership in the securities owned by the Fund except to the extent, if any, of his pecuniary interest therein. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:48 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 16,773 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001213900-17-007166 · f4063017slager_oramed.xml · derivative · entry 1 Slager David Mark · CIK 0001477733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,773 Underlying: Common Stock · 16,773 shares Expires 2027-06-30 F1 · derivative.exercise_date: The Stock Option will vest in 3 equal installments of 5,591 on each of December 31, 2017, December 31, 2018 and December 31, 2019. Read SEC document |
| February 09, 2017 Filed Feb 16, 2017 20:47 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 5,697 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001213900-17-001492 · f4020917slager_oramed.xml · derivative · entry 1 Slager David Mark · CIK 0001477733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,697 Underlying: Common Stock · 5,697 shares Expires 2027-02-09 F1 · derivative.exercise_date: The Stock Option will vest immediately. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.